This approach allows for precise intervention to prevent unwanted side effects without altering the effectiveness of tumor treatment
Munjal Acharya
The next steps involve testing the C5aR1 inhibitor PMX205 in more clinically relevant brain cancer models and radiation therapy regimens. “We plan to study PMX205 prophylactically and in combination with radiation and chemotherapy, like temozolomide, utilizing genetically engineered moutilize models and patient-derived xenografts,” declares Acharya. These experiments will better mimic clinical settings, including fractionated radiation doses typically utilized in patients. “These steps aim to translate the promising neuroprotective effects seen in mice into therapies for human brain cancer survivors at risk of cognitive decline.”
By personalizing treatment utilizing C5aR1 inhibitors like PMX205, patients can receive protection tailored to their risk of cognitive decline while undergoing brain cancer therapy. A similar pre-clinical approach for Alzheimer’s disease is being led by Acharya’s collaborator, Andrea Tenner, PhD, who also contributed to the study. “This approach allows for precise intervention to prevent unwanted side effects without altering the effectiveness of tumor treatment,” declares Acharya. “The ability to utilize a safe, brain-penetrant drug already tested in humans demonstrates how tarobtained molecular therapies can improve outcomes and quality of life for cancer survivors through precision medicine.”
Source: UC Irvine School of Medicine
Leave a Reply